UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000016861
Receipt number R000019572
Scientific Title Analysis of effect of mosapride citrate administration on increasing in type 2 diabetic patient's postprandial plasma active glucagon-like peptide-1
Date of disclosure of the study information 2015/03/21
Last modified on 2019/02/11 11:20:08

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Analysis of effect of mosapride citrate administration on increasing in type 2 diabetic patient's postprandial plasma active glucagon-like peptide-1

Acronym

Effect of mosapride citrate in type 2 diabetic patient's GLP-1

Scientific Title

Analysis of effect of mosapride citrate administration on increasing in type 2 diabetic patient's postprandial plasma active glucagon-like peptide-1

Scientific Title:Acronym

Effect of mosapride citrate in type 2 diabetic patient's GLP-1

Region

Japan


Condition

Condition

Type 2 diabetes

Classification by specialty

Endocrinology and Metabolism

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To reveal the effect of mosapride citrate on increasing type 2 diabetic patient's postprandial plasma active GLP-1

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

Difference between 2 groups' amount of 60 minutes postprandial plasma active GLP-1 change after 2 weeks administration of test drug or comparative drug from baseline

Key secondary outcomes

Difference of 60 minutes postprandial plasma active GLP-1 change between before and after 2 weeks administration of test drug or comparative drug and difference between 2 groups' of glycoalbmin, 60 minutes postprandial insulin, glucose, HOMA-R, HOMA-beta, and frequency of stool


Base

Study type

Interventional


Study design

Basic design

Cross-over

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification

NO

Dynamic allocation

NO

Institution consideration


Blocking

NO

Concealment

No need to know


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

60 min postprandial blood withdrawal
Test drug (mosapride citrate) 15mg/day for 2 weeks
60 min postprandial blood withdrawal
Washout period (4-8 weeks)
60 min postprandial blood withdrawal
Comparative drug (dompridone) 30mg/day for 2 weeks
60 min postprandial blood withdrawal

Interventions/Control_2

60 min postprandial blood withdrawal
Comparative drug (dompridone) 30mg/day for 2 weeks
60 min postprandial blood withdrawal
Washout period (4-8 weeks)
60 min postprandial blood withdrawal
Test drug (mosapride citrate) 15mg/day for 2 weeks
60 min postprandial blood withdrawal

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

85 years-old >

Gender

Male and Female

Key inclusion criteria

1) Type 2 diabetic patients
2) Glycoalbmin < 26.0 %
3) BMI < 30.0
4) Patient explained and informed with the written consent

Key exclusion criteria

1) Type 1 diabetic patients
2) Patient with a history of diabetic coma within 6 months
3) Necessity of insulin such as severe infection, perioperative period, and severe external injury
4) Severe hepatic and renal disorder (Ccr < 30mL/min, serum Cre > 2.0 mg/dl (female), 2.5 mg/dl (male), Child-Pugh grade C)
5) Severe gastrointestinal dysfunction
6) Patient administrated drugs with the same indications of test drug or comparative drug, insulin GLP-1 analog, or DPP4 inhibitor, or treated by 4 or more diabetes drug
7) Pregnant female, lactating female, or female with possibility or planning of pregnancy
9) Patients evaluated incompetent by doctors in attendance

Target sample size

16


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Makoto Arai

Organization

Chiba University Hospital

Division name

Gastroenterology

Zip code


Address

Department of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University (K1), 1-8-1, Inohana, Chuo-ku, Chiba-shi, Chiba-ken, 260-8670, Japan

TEL

043-226-2083

Email

araim-cib@umin.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Daisuke Maruoka

Organization

Chiba University Hospital

Division name

Gastroenterology

Zip code


Address

1-8-1, Inohana, Chuo-ku, Chiba-shi, Chiba-ken, 260-8670, Japan

TEL

043-226-2083

Homepage URL


Email

maruoka-cib@umin.ac.jp


Sponsor or person

Institute

Chiba University

Institute

Department

Personal name



Funding Source

Organization

Chiba University

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

千葉大学医学部附属病院(千葉県)


Other administrative information

Date of disclosure of the study information

2015 Year 03 Month 21 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2015 Year 02 Month 28 Day

Date of IRB


Anticipated trial start date

2015 Year 04 Month 01 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2015 Year 03 Month 21 Day

Last modified on

2019 Year 02 Month 11 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000019572


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name